Annual report pursuant to Section 13 and 15(d)

Schedule of Diluted Net Loss Per Share (Details)

v3.24.1
Schedule of Diluted Net Loss Per Share (Details) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents 657,980
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents 232,677
Series A Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents 283,512